All In Biotech

Drug Trial Radar · NCT01603407

Finding the Optimum Regimen for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy: Double-blind Randomized Trial to Find Optimum Steroid Regimen

Last checked: Nov 19, 2026Latest source record: Aug 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 196 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

196

Actual

Start

Jan 2013

Primary completion

Nov 2019

Study completion Nov 2019

Sponsor

Lead sponsor
University of RochesterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Newcastle University; University Medical Center Freiburg; National Institute of Neurological Disorders and Stroke (NINDS)
First posted
May 23, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 4 years, up to 7 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Finding the Optimum Regimen for Duchenne Muscular Dystrophy (FOR DMD) study will compare three ways of giving corticosteroids to boys with Duchenne muscular dystrophy (DMD) to determine which of the three ways increases muscle strength the most, and which causes the fewest side effects. Using the results of this study, the investigators aim to provide patients and families with clearer information about the best way to take these drugs.

Conditions

  • Duchenne Muscular Dystrophy

Interventions

  • PrednisoneDrug

    daily prednisone (0.75 mg/kg/day) tablets for 36-60 months

  • PrednisoneDrug

    intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months

  • DeflazacortDrug

    daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Forced Vital CapacityTime frame: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
  2. Rise From the Floor VelocityTime frame: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits
  3. Treatment Satisfaction Questionnaire for Medication (TSQM) Global Satisfaction With Treatment ScoreTime frame: Average of Months 3, 6, 12, 18, 24, 30 and 36 visits

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles (UCLA) Medical Center

    Los Angeles, California

  • University of California Davis Medical Center

    Sacramento, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Nemours Children's Hospital

    Orlando, Florida

  • Ann and Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of New Mexico Health Science Center

    Albuquerque, New Mexico

  • University of Rochester Medical Center

    Rochester, New York

  • University of North Carolina at Chapel Hill

    Chapel Hill, North Carolina

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania

  • Vanderbilt Children's Hospital

    Nashville, Tennessee

  • University of Utah Medical Center

    Salt Lake City, Utah

  • Alberta Children's Hospital

    Calgary, Alberta, Canada

  • Children's Hospital London Health Sciences Centre

    London, Ontario, Canada

  • Children's Hospital of Eastern Ontario (CHEO)

    Ottawa, Ontario, Canada

  • Children's Hospital, Technical University Dresden

    Dresden, Germany

  • University Hospital of Essen

    Essen, Germany

  • University Medical Center Freiburg

    Freiburg im Breisgau, Germany

  • Children's University Hospital, Göttingen

    Göttingen, Germany

  • University of Messina AOU Policlinico Gaetano Martino

    Messina, Italy

  • C. Besta Neurological Institute Foundation

    Milan, Italy

  • University of Padova School of Medicine

    Padova, Italy

  • Neuromuscular Center University of Turin

    Torino, Italy

  • Heart of England NHS Foundation Trust Birmingham Heartland's Hospital

    Birmingham, United Kingdom

  • Alder Hey Children's Hospital NHS Trust

    Liverpool, United Kingdom

  • Great Ormond Street Hospital for Children NHS Trust

    London, United Kingdom

  • Royal Manchester Children's Hospital

    Manchester, United Kingdom

  • Institute of Human Genetics, International Centre for Life

    Newcastle upon Tyne, United Kingdom

  • The General Infirmary at Leeds

    Leeds, England, United Kingdom

  • Greater Glasgow and Clyde NHS Yorkhill Hospital

    Glasgow, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.